Charles River Laboratories (NYSE: CRL) revenue
Charles River Laboratories reported revenue of $4,015m for fiscal 2025, 0.9% less than in fiscal 2024 ($4,050m). Since fiscal 2016 its revenue has grown by 138.8%, an average growth of 10.2% a year.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $4,015m | −0.9% | $25.2m | 0.6% |
| 2024 | $4,050m | −1.9% | $227.3m | 5.6% |
| 2023 | $4,129m | +3.9% | $617.3m | 14.9% |
| 2022 | $3,976m | +12.3% | $651.0m | 16.4% |
| 2021 | $3,540m | +21.1% | $589.9m | 16.7% |
| 2020 | $2,924m | +11.5% | $432.7m | 14.8% |
| 2019 | $2,621m | +15.7% | $351.2m | 13.4% |
| 2018 | $2,266m | +22.0% | $331.4m | 14.6% |
| 2017 | $1,858m | +10.5% | $288.3m | 15.5% |
| 2016 | $1,681m | — | $237.6m | 14.1% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Questions about the revenue of Charles River Laboratories
- How much revenue did Charles River Laboratories make in fiscal 2025?
- Charles River Laboratories reported revenue of $4,015m for fiscal 2025, compared with $4,050m in fiscal 2024.
- How much has the revenue of Charles River Laboratories grown?
- Between fiscal 2016 and fiscal 2025 it went from $1,681m to $4,015m: 138.8% more, an average growth of 10.2% a year.
- What was the best year for revenue at Charles River Laboratories?
- Of its last 10 fiscal years, fiscal 2023, with $4,129m.
- Where do the figures for Charles River Laboratories come from?
- From the annual report (Form 10-K) that Charles River Laboratories files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Charles River Laboratories files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Charles River Laboratories: the Charles River Laboratories page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.